| Dexamethasone use | DOAC dose | Indication | New/chronic users | Age | Sex | Weight (kg) | eGFR (mL/min) |
DOAC trough level (ng/mL) |
DOAC peak level (ng/mL) |
|---|---|---|---|---|---|---|---|---|---|
| Yes |
Apixaban 2.5 mg bid |
AF AF AF |
New New New |
88 95 80 |
M M M |
78 66 79 |
35 19 56 |
179 (high) 36 150 |
227 (high) 69 170 |
|
Apixaban 5 mg bid |
AF VTE |
Chronic New |
84 66 |
F M |
109 87 |
80 132 |
122 32 |
182 110 |
|
|
Apixaban 10 mg bid |
VTE | New | 82 | M | 69 | 41 | 192 | 308 | |
|
Rivaroxaban 10 mg od |
Post AMI | Chronic | 78 | M | 78 | 82 | 41 (high) | 125 | |
|
Rivaroxaban 15 mg od |
AF | New | 86 | F | 67 | 43 | 52 | 283 | |
|
Rivaroxaban 20 mg od |
AF AF AF AF |
Chronic New New New |
86 83 74 71 |
M M M M |
68 90 110 116 |
66 89 75 90 |
81 64 76 26 |
545 (high) 306 263 158 (low) |
|
|
Rivaroxaban 15 mg bid |
VTE | New | 77 | F | 62 | 88 | 79 | 256 | |
|
Edoxaban 60 mg od |
VTE VTE VTE |
Chronic New New |
79 84 72 |
M F M |
94 76 80 |
61 61 90 |
64 (high) 35 28 |
347 (high) 388 (high) 223 |
|
| No |
Apixaban 2.5 mg bid |
AF AF AF |
New Chronic New |
85 90 73 |
F M M |
62 73 96 |
23 43 28 |
99 85 107 |
121 91 156 |
|
Apixaban 10 mg bid |
VTE | New | 60 | M | 88 | 82 | 61 | 286 |